OR WAIT null SECS
January 12, 2016.
The Parkinson’s disease treatment pipeline "holds significant potential for patients and investors", says GBI Research.
According to the company’s latest report, the current Parkinson’s disease pipeline is highly active, consisting of 365 programs across all stages of development and a diverse range of molecular targets.
GBI analyst Angel Wong Wong explained that as the majority of potentially disease-modifying treatments are in the early stages of development, they are expected to fulfill a huge unmet need in the Parkinson’s disease treatment market in the long term.
The report also states that there are 94 first-in-class products available for strategic consolidations, meaning a vast number of investment opportunities are available for licensing or co-development deals in Parkinson’s disease therapeutics.